Home

Our Technology

Innovative Chemistry
Transformative Therapies

FDA “Fast Track” and “Breakthrough Therapy” designations received. 

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation Read More
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study Read More
Ensysce Biosciences Accelerates PF614-MPAR-102 Study Read More
Ensysce Biosciences to Showcase “A New Era in Pain Therapeutics” at PAINWeek 2026 Symposium Read More
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer